Mannin Research Inc.
Mannin Research Inc. (Mannin), is a biotechnology company leading the development of a new class of vascular therapeutics. The drug development program is led by Mannin’s Chief Scientific Officer, the world renowned, Dr. Susan Quaggin, Chief of the Division of Nephrology and Director of the Feinberg Cardiovascular Research Institute at Northwestern University in Chicago.
Utilizing a proprietary research platform, only recently published (September 2014) in the Journal of Clinical Investigations, this technology is addressing the need for a new class of drugs to treat diseases such as Glaucoma and Cystic Kidney disease. Our primary target indication is for a First-In-Class therapeutic eye drop for the treatment of Glaucoma in adults and children.
What is Glaucoma?
Watch this short video from the Glaucoma Research Foundation to get a better understanding of Glaucoma and its causes.